The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma <scp>XI’</scp> , a multicentre, open‐label, randomised, phase III trial-Reference-Cited by-同舟云学术

The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’ , a multicentre, open‐label, randomised, phase III trial

Published:2022-12-21 Issue:2 Volume:201 Page:267-279
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Jenner Matthew W.¹,Pawlyn Charlotte²³^ORCID,Davies Faith E.⁴,Menzies Tom⁵,Hockaday Anna⁵,Olivier Catherine⁵,Jones John R.⁶⁷⁸,Karunanithi Kamaraj⁹,Lindsay Jindriska¹⁰,Kishore Bhuvan¹¹,Cook Gordon⁵¹²^ORCID,Drayson Mark T.¹³,Kaiser Martin F.²³^ORCID,Owen Roger G.¹⁴,Gregory Walter⁵,Cairns David A.⁵^ORCID,Morgan Gareth J.⁴,Jackson Graham H.¹⁵^ORCID,

Affiliation:

1. University Hospital Southampton NHS Foundation Trust Southampton UK

2. The Institute of Cancer Research London UK

3. The Royal Marsden NHS Foundation Trust London UK

4. Perlmutter Cancer Center, NYU Langone Health New York USA

5. Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research University of Leeds Leeds UK

6. Eastbourne District General Hospital Eastbourne UK

7. Brighton and Sussex Medical School University of Sussex Sussex UK

8. Kings College Hospital NHS Foundation Trust London UK

9. University Hospitals of North Midlands NHS Trust Stoke‐on‐Trent UK

10. East Kent Hospitals University NHS Foundation Trust Canterbury UK

11. University Hospitals Birmingham NHS Foundation Trust Birmingham UK